Thursday, February 10, 2011
Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS
Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment